Key result
EXP3174 lowers mean arterial pressure by ~23% without compromising myocardial blood flow.
Why the study?
The role of the renin-angiotensin system in regulation of myocardial tissue perfusion and the comparative systemic and coronary effects of the AT1 receptor antagonist EXP3174 versus the ACE inhibitor enalaprilat were unclear.
Does EXP3174 alter systemic and coronary hemodynamics or regional myocardial blood flow compared to enalaprilat in anesthetized dogs?
Population
Anesthetized, open-chest dogs with or without preactivated renin-angiotensin system
Comparison
EXP3174 (0.03-0.3 mg/kg) vs enalaprilat (0.1-1 mg/kg)
Design
Preclinical experimental study
Authors
Loading...
Suggests AT1 blockade mimics ACE inhibition hemodynamically without coronary effects in dogs; leaves open whether RAS regulates myocardial perfusion in patients.
Does EXP3174 alter systemic and coronary hemodynamics or regional myocardial blood flow compared to enalaprilat in anesthetized dogs?
Blockade of the AT1 receptor by EXP3174 induces hemodynamic modifications similar to the ACE inhibitor enalaprilat, but neither affects regional myocardial blood flow, suggesting the RAS does not regulate myocardial tissue perfusion in this model.
Richard et al. (1993) studied Preactivated renin-angiotensin system. EXP3174 vs. Enalaprilat (0.1-1 mg/kg) was evaluated on Systemic and coronary hemodynamics and regional myocardial blood flow. In dogs with preactivated RAS, EXP3174 induced a dose-dependent decrease in mean arterial blood pressure (maximum decrease -23 +/- 7%) similar to enalaprilat, without affecting myocardial blood flow.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: